10月9日，药康生物跌2.33%，成交额4314.67万元。两融数据显示，当日药康生物获融资买入额606.84 万元，融资偿还593.61万元，融资净买入13.23万元。截至10月9日，药康生物融资融券余额合计6976.96 万元。 分红方面，药康生物A股上市后累计派现1.39亿元。 融资方面，药康生物当日融资买入606.84万元。当前融资余额6953.69万元，占流通市值的0.96%，融资 余额低于近一年50%分位水平，处于较低位。 融券方面，药康生物10月9日融券偿还600.00股，融券卖出200.00股，按当日收盘价计算，卖出金额 3528.00元；融券余量1.32万股，融券余额23.28万元，超过近一年60%分位水平，处于较高位。 资料显示，江苏集萃药康生物科技股份有限公司位于江苏省南京市江北新区学府路12号，成立日期2017 年12月29日，上市日期2022年4月25日，公司主营业务涉及实验动物小鼠模型的研发、生产、销售及相 关技术服务。主营业务收入构成为：商品化小鼠模型销售55.36%，功能药效23.46%，定制繁育 11.32%，模型创制7.06%，代理进出口及其他2.70%，其他(补充)0.0 ...

Group 1 - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. was established on December 29, 2017, and went public on April 25, 2022, with a current market capitalization of 7.934 billion yuan [1] - The company's main business involves the research, production, sales, and related technical services of laboratory mouse models, with revenue composition as follows: commercial mouse model sales 55.36%, functional efficacy 23.46%, custom breeding 11.32%, model creation 7.06%, and agency import/export and others 2.70% [1] Group 2 - Noan Fund's Noan Pioneer Mixed A (320003) is among the top ten circulating shareholders of Yaokang Biotechnology, having reduced its holdings by 1.0721 million shares in the second quarter, now holding 5.3339 million shares, which is 1.3% of circulating shares [2] - The fund has achieved a year-to-date return of 29.91% and a one-year return of 60.29%, ranking 2678 out of 8246 and 2184 out of 8054 respectively [2] Group 3 - The fund manager of Noan Pioneer Mixed A is Yang Gu, who has a cumulative tenure of 19 years and 211 days, with the fund's total asset size at 5.133 billion yuan [3] - During Yang Gu's tenure, the best fund return was 1033.17%, while the worst was 3.03% [3]

Core Insights - Jiangsu Jicui Pharmaceutical Technology Co., Ltd. (药康生物) has shown a mixed performance in its financial metrics, with a revenue increase but a decline in net profit [2][3] - The company has a significant presence in the market for laboratory mouse models, with a diverse revenue stream from various business segments [1] Financial Performance - For the first half of 2025, the company reported a revenue of 375 million yuan, representing a year-on-year growth of 10.11% [2] - The net profit attributable to shareholders was approximately 70.91 million yuan, reflecting a year-on-year decrease of 7.12% [2] Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 23.68% to 7,213, with an average of 56,841 circulating shares per shareholder, up by 62.56% [2] - On September 1, 2023, the company's stock price increased by 1.31%, with a trading volume of approximately 59.66 million yuan [1] Financing and Margin Trading - On September 1, 2023, the company had a net financing outflow of 1.61 million yuan, with a total financing balance of 112 million yuan, accounting for 1.54% of its market capitalization [1] - The margin trading data indicates a high financing balance, while the short selling activity remains relatively low, with a short selling balance of 196,300 yuan [1] Dividend Distribution - Since its A-share listing, the company has distributed a total of 139 million yuan in dividends [3] Institutional Holdings - As of June 30, 2025, notable institutional shareholders include China Europe Medical Health Mixed Fund and others, with some institutions reducing their holdings [3]

Core Viewpoint - The report outlines Shanghai Southern Model Biotechnology Co., Ltd.'s efforts to enhance operational quality, increase investor returns, accelerate the development of new productive forces, strengthen investor communication, and ensure regulatory compliance in the first half of 2025 [1][4][7][8]. Group 1: Enhancing Operational Quality - The company focuses on life sciences, expanding its mouse model library and improving service quality while enhancing production capacity and information technology [1]. - As of the first half of 2025, the company has nine production and R&D bases with a total capacity of approximately 140,000 cages, and a major expansion project is underway at its headquarters [3]. Group 2: Increasing Investor Returns - The company reported a net profit of RMB 6.4955 million for 2024, marking a return to profitability, but decided not to distribute profits to support future growth and innovation [4][5]. - The company aims to balance shareholder returns with sustainable development, exploring methods to enhance both immediate and long-term shareholder benefits [5]. Group 3: Accelerating Development of New Productive Forces - The company has developed over 22,000 models, including more than 14,000 standardized models, to meet market demands in drug research and development [5]. - The company is advancing the development of humanized mouse models for various therapeutic areas, including cancer and genetic diseases, and has validated over 200 models in the first half of 2025 [5]. Group 4: Strengthening Investor Communication - The company emphasizes transparency and compliance with information disclosure regulations, actively engaging with investors through various channels [7]. - The company participated in performance briefings and maintained a high response rate to investor inquiries, fostering two-way communication [7]. Group 5: Ensuring Regulatory Compliance - The company has implemented a stock incentive plan and conducted multiple board meetings to ensure compliance with corporate governance standards [8][9]. - The company is in the process of revising its articles of association and enhancing its internal control systems to maintain a stable governance structure [9]. Group 6: Strengthening Key Personnel Responsibility - The company has established a stock incentive plan to motivate key personnel, linking performance metrics to revenue growth [10]. - Training programs for board members and senior management are being conducted to enhance compliance awareness and operational effectiveness [10].

北京时间2025年4月11日凌晨美国FDA发布了减少临床前安全研究中动物试验的路线图，该路线图希望 通过科学验证的新方法，如芯片上的器官系统、计算建模和先进的体外检测，减少大规模使用、重复性 动物标本的临床试验。 药康生物表示，实际FDA的举措与公司的企业研发及战略发展方向一致。公司一直致力于发展例如斑点 鼠、人源化模型、野化鼠、无菌鼠等多种改造模型，一代代革新技术以求这些模型能够更加真实地模拟 人类的生物学特性，使得疾病机制的研究、药物筛选和临床前实验更加接近真实人体环境，通过为科研 及工业客户提供更个性化的真实模型，极大地提高了研发的可靠性和转化效率，也减少了动物的损耗。 例如高质量的人源化小鼠模型，通过Tg（转基因）、KO（基因敲除）、KI（基因敲入）等先进的基因 工程技术，使小鼠在基因、免疫系统、特定细胞、组织以及微生物群落中表达与人类相似的生物特征。 公司表示，由于抗体药物成药的分子形式和作用机制越来越多样化，药物研发的需求目前很难通过单个 类别的评价方式提供最优解，公司主要模式动物产品及基于疾病动物服务具备极高的多样性、有效性和 可靠性，能够为药物研发提供不可替代的机制研究和验证作用。 综合评估， ...